Abstract
Background/Aim: Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC).
Patients and Methods: We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively.
Results: Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p<0.001; OS: p<0.001 and p<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95% confidence interval (CI)=1.154-9.538; p=0.026).
Conclusion: Pre-treatment NLR is a predictor of poor prognosis in EC.
| Original language | English |
|---|---|
| Pages (from-to) | 337-344 |
| Number of pages | 8 |
| Journal | Anticancer research |
| Volume | 35 |
| Issue number | 1 |
| Publication status | Published - Jan 1 2015 |
Keywords
- Endometrial cancer
- Neutrophil to lymphocyte ratio
- Prognosis
ASJC Scopus subject areas
- Oncology
- Cancer Research
